美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Corgi All World 2x Daily ETF

24.25

0.0000

成交量：9

成交額：212.29

市值：36.38萬

市盈率：- -

高：24.25

開：24.25

低：24.25

收：24.25

52周最高：25.58

52周最低：20.48

股本：1.50萬

流通股本：1.50萬

量比：0.10

換手率：0.06%

股息：- -

股息率：- -

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

國產創新藥迎三重業績拐點 CXO龍頭利潤與訂單同步創出歷史新高

CXO開啓主升浪，藥明系、金斯瑞、康龍等集體突破！華寶基金港股通醫療ETF創5個月收盤新高，醫療ETF8天7陽

CXO再度爆發，藥明康德H股叒新高！華寶基金港股通醫療ETF（159137）上探3.5%，標的指數CXO含量全市場第一

強業績引爆CXO行情，哪個可投資指數CXO含量最高？

訂單飽滿結構升級 CXO企業半年度業績釋放回暖信號

醫藥行業的轉折時刻到了

聯想引爆港股硬科技，159131衝高逾4%！CXO捲土重來，華寶基金醫療ETF創6個月新高！

美銀證券：中國CXO行業受惠生物科技融資強勁上調藥明康德等目標價

CXO強者恒強！藥明康德AH股齊升，皓元醫藥升逾8%！華寶基金醫療ETF（512170）升逾2%衝擊五連陽

醫藥調研熱度超越半導體！創新藥回調，華寶基金港股通創新藥ETF失守半年線！CXO韌性十足，藥明系逆市飄紅

港股異動 | CRO概念股繼續走高藥明康德司法取得進展有利於CXO公司在海外爭取新的訂單

衝高回落，CXO狂歡要散場了？

私募排排网

創新藥+CXO齊發力，中報驗證產業向上大趨勢？

AI製藥點燃「賣鏟人」行情，CXO巨頭刷新多項紀錄！創新藥接棒在即？基金經理最新解讀來了！

智通港股早知道 | SK海力士批准54萬億韓元芯片擴產計劃非京籍家庭購房社保個税繳納年限下調為一年

好「藥」知時節！8月創新藥能否扛大旗？CXO全線爆發，華寶基金港股通醫療ETF放量勁漲5.51%

業績的力量，CXO巨頭單周暴漲20%！創新藥高景氣持續驗證

CXO帶飛醫療，華寶基金醫療ETF（512170）勁漲3%再創階段新高！多股升逾10%，凱萊英漲停封板

港股CXO近日股價集體走高，盈警之後的泰德醫藥(03880)將逆市下跌還是超跌反彈？

【券商聚焦】中信建投：CXO 行業復甦明確，海內外醫藥投融資同步回暖

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.imtigers.com/hant/stock/WX/news?page=2"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"WX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"WX\",,,,,undefined,":{"symbol":"WX","market":"US","secType":"STK","nameCN":"Corgi All World 2x Daily ETF","latestPrice":24.2537,"timestamp":1789482882285,"preClose":24.2537,"halted":0,"volume":9,"delay":0,"changeRate":0,"floatShares":15000,"shares":15000,"eps":0,"marketStatus":"交易中","change":0,"latestTime":"09-15 11:51:35 EDT","open":24.2537,"high":24.2537,"low":24.2537,"amount":212.29000200000002,"amplitude":0,"askPrice":24.03,"askSize":300,"bidPrice":23.96,"bidSize":300,"shortable":3,"etf":2,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1789502400000},"marketStatusCode":2,"adr":0,"exchange":"CBOE","adjPreClose":24.2537,"nav":24.6,"aum":369000,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":24.6313,"preClose":24.2537,"latestTime":"16:10 EDT","volume":6,"amount":145.5222,"timestamp":1789416604212,"change":0.3776,"changeRate":0.015569,"amplitude":0},"volumeRatio":0.096556},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"WX\",,,,,undefined,":{"symbol":"WX","floatShares":15000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.096556,"shares":15000,"dividePrice":0,"high":24.2537,"amplitude":0,"preClose":24.2537,"low":24.2537,"week52Low":20.48,"pbRate":"--","week52High":25.58,"institutionHeld":0,"latestPrice":24.2537,"eps":0,"divideRate":0,"volume":9,"delay":0,"ttmEps":0,"open":24.2537,"prevYearClose":24.72,"prevWeekClose":24.6313,"prevMonthClose":24.9073,"prevQuarterClose":23.5672,"fiveDayClose":24.9446,"twentyDayClose":25.3738,"sixtyDayClose":23.76},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/WX\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"WX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"WX\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"WX\",pageSize:20,pageCount:2,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2660490014","title":"國產創新藥迎三重業績拐點 CXO龍頭利潤與訂單同步創出歷史新高","url":"https://stock-news.laohu8.com/highlight/detail?id=2660490014","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660490014?lang=zh_tw&edition=fundamental","pubTime":"2026-08-19 07:25","pubTimestamp":1787095509,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["CXO","MEDX","LNGR","WX","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660464424","title":"CXO開啓主升浪，藥明系、金斯瑞、康龍等集體突破！華寶基金港股通醫療ETF創5個月收盤新高，醫療ETF8天7陽","url":"https://stock-news.laohu8.com/highlight/detail?id=2660464424","media":"新浪基金","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660464424?lang=zh_tw&edition=fundamental","pubTime":"2026-08-18 19:45","pubTimestamp":1787053500,"startTime":"0","endTime":"0","summary":"8月18日，CXO强者恒强，继续领涨医疗板块！场内高CXO含量ETF继续上行，港股通医疗ETF华宝标的指数CXO含量全市场第一，场内价格续涨1.25%创5个月收盘新高！全市场规模最大医疗ETF华宝CXO含量超30%，斩获8天7阳。药明康德半年度净利润历史首次突破百亿元大关，并大幅上调全年指引；康龙化成Q2收入和经调利润分别同比增长19.38%和22.3%；昭衍新药上半年归母净利润同比预增884.9%至1377.4%。其中药明系占比超38%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-08-18/doc-inintxxh8569801.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["FLHK","159828","WX","CXO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660138101","title":"CXO再度爆發，藥明康德H股叒新高！華寶基金港股通醫療ETF（159137）上探3.5%，標的指數CXO含量全市場第一","url":"https://stock-news.laohu8.com/highlight/detail?id=2660138101","media":"新浪基金","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660138101?lang=zh_tw&edition=fundamental","pubTime":"2026-08-17 11:19","pubTimestamp":1786936740,"startTime":"0","endTime":"0","summary":"8月17日，港股通医疗板块强势反弹，CXO再度领涨，药明康德港股再创历史新高！场内热门ETF方面，可T+0交易的港股通医疗ETF华宝盘中上探3.5%收复5日线！数据显示，其标的指数CXO含量达52.5%，在全市场可投资指数中为最高，其中药明系权重占比超38%，同样高居首位。最新CXO含量达32.82%，其中药明康德（A股）占比13.42%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-08-17/doc-ininqtns0348637.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU1979443071.USD","BK1583","LU0320764599.SGD","LU2242644610.SGD","159828","LU1997245177.USD","BK0216","IE00B543WZ88.USD","LU0708995583.HKD","LU2045819591.USD","LU0611395673.USD","LU0572944931.SGD","159137","IE00BPRC5H50.USD","LU1808992512.USD","LU0700851271.USD","LU1997245094.SGD","LU2328871848.SGD","LU1934453819.USD","BK1576","IE00B5MMRT66.SGD","02359","WX","LU2488822045.USD","LU0052750758.USD","LU0456842615.SGD","LU1303224171.USD","LU1251922891.USD","BK1141","LU1969619763.USD","LU0348767384.USD","LU0348766576.USD","LU1770034418.SGD","CXO","LU0327786744.USD","603259","LU1719994722.HKD","FLHK","LU1046422090.SGD","LU2125910500.SGD","LU2495084118.USD","LU1997244956.HKD","LU0469268626.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660810134","title":"強業績引爆CXO行情，哪個可投資指數CXO含量最高？","url":"https://stock-news.laohu8.com/highlight/detail?id=2660810134","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660810134?lang=zh_tw&edition=fundamental","pubTime":"2026-08-17 11:03","pubTimestamp":1786935780,"startTime":"0","endTime":"0","summary":"🔥药明康德交出史上最强中报🚀CXO行业景气上行持续验证一键投资CXO，关注T+0利器👇🏻🔥港股通医疗ETF华宝#159137❤️标的指数CXO含量52.5%，全市场第一❗💙其中药明系权重占比超38%🐲投龙头·选华宝⚠️市场有风险，投资须谨慎","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-08-17/doc-ininqtnu9181150.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["CXO","WX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659612294","title":"訂單飽滿結構升級 CXO企業半年度業績釋放回暖信號","url":"https://stock-news.laohu8.com/highlight/detail?id=2659612294","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659612294?lang=zh_tw&edition=fundamental","pubTime":"2026-08-15 07:30","pubTimestamp":1786750211,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["WX","CXO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659691001","title":"醫藥行業的轉折時刻到了","url":"https://stock-news.laohu8.com/highlight/detail?id=2659691001","media":"虎嗅APP","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659691001?lang=zh_tw&edition=fundamental","pubTime":"2026-08-13 21:27","pubTimestamp":1786627620,"startTime":"0","endTime":"0","summary":"以日为镜，产业拐点已现复盘全球资本市场，中国医药行业正处在与日本90年代高度相似的十字路口。上世纪80年代末，日本医药行业同样面临\"人口老龄化+医保控费\"的双重压力。但硬币有两面，这个过程反而使日本医药行业获得了新的机会。自此日本医药行业基本面开始从国内控费周期，走向创新和全球化周期。这是中国医药区别于日本、天花板更高的根本所在。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MTQzMjE1NjQwMQ==&mid=2656193644&idx=1&sn=31e46f943a0b4679b80bf093d14a52ce&chksm=67a87e0cebd46e7c844b957a1f14f55a9a5c0f2479a16a54cad7a66703e950939a896e1368f5&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["MEDX","06160","BK1583","LU0307460666.USD","BK1574","LNGR","09939","LU0828237510.HKD","LU1770034418.SGD","LU1719994722.HKD","BK1515","LU0588546209.SGD","IBBQ","BK1588","LU1251922891.USD","BK1161","LU2328871848.SGD","06978","LU0228659784.USD","WX","LU1303224171.USD","BK1500","LU1969619763.USD","KURE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659315910","title":"聯想引爆港股硬科技，159131衝高逾4%！CXO捲土重來，華寶基金醫療ETF創6個月新高！","url":"https://stock-news.laohu8.com/highlight/detail?id=2659315910","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659315910?lang=zh_tw&edition=fundamental","pubTime":"2026-08-13 19:20","pubTimestamp":1786620000,"startTime":"0","endTime":"0","summary":"联想集团炸裂财报催化，同类规模最大、流动性最强*的港股通信息技术ETF华宝场内价格一度冲高逾4%，收涨2.99%强势连阳。CXO卷土重来，全市场规模最大医疗ETF华宝盘中最高涨至2.86%上探创近6个月新高，收涨1.43%豪取五连阳。联想集团飙升19%创新高！值得注意的是，港股通信息技术权重股联想科技一度涨超19%创历史新高。CXO再度领衔，华宝基金医疗ETF逆市创6个月新高！底层资产是港股，高弹性，T+0。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-08-13/doc-inineqhp9946806.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["03441","LU0543330483.HKD","HK0000320223.HKD","BK1193","LU0320764755.SGD","HK0000306701.USD","LU0862451837.USD","LU1366334578.USD","LU0890818403.SGD","BK4585","IE0003895053.USD","LU0572939691.SGD","IE0034224299.USD","TCHI","LU1267930227.SGD","LU2242644610.SGD","LU0370786039.SGD","LU1235295612.USD","LU0672654166.SGD","IE00B0JY6N72.USD","LU0052756011.USD","HK0000306685.HKD","LU0128525689.USD","00992","LU0128522157.USD","LU1366334651.USD","IE0032431581.USD","CXO","LU0049112450.USD","VXUS","LU0048580855.USD","LU0791591158.USD","LU0862451753.SGD","80992","LU0310800965.SGD","LU1046422090.SGD","KCAI","BK1526","159828","159131","WX","BK1607","LU0264606111.USD","LU0029875118.USD","LU0791590937.USD","LNVGY","LU0572940350.SGD","HK0000320264.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659138517","title":"美銀證券：中國CXO行業受惠生物科技融資強勁 上調藥明康德等目標價","url":"https://stock-news.laohu8.com/highlight/detail?id=2659138517","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659138517?lang=zh_tw&edition=fundamental","pubTime":"2026-08-13 12:41","pubTimestamp":1786596060,"startTime":"0","endTime":"0","summary":"模拟交易客户端美银证券发布研报称，受惠上半年全球及中国生物科技一级市场融资表现强劲，加上创新药对外授权交易持续活跃，预期研发活动将进一步加快，中国CRO/CDMO企业可望受惠。该行上调药明康德H股目标价由204.3港元至242港元，药明康德A股目标价由177.8元人民币至210.5元人民币，维持“买入”评级，因其增长能见度清晰。该行并上调药明康德2029至2035年收入估算介乎3%至7%，经调整纯利预测亦上调介乎3%至7%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/hkgg/2026-08-13/doc-inincxku3329313.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["161027","IBRN","APXH","02359","603259","BMED","CXO","BBC","SURI","WX","MEDI","XBIX","IDNA","LFSC","PSIL","PSCH","SMCO","FHLC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659187744","title":"CXO強者恒強！藥明康德AH股齊升，皓元醫藥升逾8%！華寶基金醫療ETF（512170）升逾2%衝擊五連陽","url":"https://stock-news.laohu8.com/highlight/detail?id=2659187744","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659187744?lang=zh_tw&edition=fundamental","pubTime":"2026-08-13 11:25","pubTimestamp":1786591500,"startTime":"0","endTime":"0","summary":"8月13日，AH医疗板块迅速反弹。CXO强者恒强，药明康德AH股双双涨逾1%，康龙化成AH股齐升逾4%，A股皓元医药涨超7%。场内高CXO含量ETF同步走走强，CXO含量超50%的港股通医疗ETF华宝涨逾1%。全市场规模最大医疗ETF华宝CXO含量超30%，盘中涨超2%冲击五连阳，成交超4.5亿元。紧跟医疗反攻行情，关注两大“利器”：港股通医疗ETF华宝：最新CXO含量达51.88%，其中药明系权重占比超38%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-08-13/doc-ininctaw3414344.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU1969619763.USD","LU1997244956.HKD","603259","LU1997245177.USD","LU2125910500.SGD","688131","LU0348767384.USD","BK1576","02359","LU1303224171.USD","LU0611395673.USD","LU1719994722.HKD","512170","LU2495084118.USD","LU0052750758.USD","LU0348766576.USD","LU1808992512.USD","LU1251922891.USD","CXO","LU1979443071.USD","IE00B5MMRT66.SGD","IE00B543WZ88.USD","LU2242644610.SGD","LU2488822045.USD","BK0216","WX","LU2045819591.USD","BK1583","LU2328871848.SGD","LU1934453819.USD","LU0708995583.HKD","BK1141","LU1046422090.SGD","LU0456842615.SGD","LU0700851271.USD","159828","IE00BPRC5H50.USD","LU0320764599.SGD","LU1770034418.SGD","LU1997245094.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658288069","title":"醫藥調研熱度超越半導體！創新藥回調，華寶基金港股通創新藥ETF失守半年線！CXO韌性十足，藥明系逆市飄紅","url":"https://stock-news.laohu8.com/highlight/detail?id=2658288069","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658288069?lang=zh_tw&edition=fundamental","pubTime":"2026-08-12 11:02","pubTimestamp":1786503720,"startTime":"0","endTime":"0","summary":"业绩兑现叠加AI制药概念加持，CXO韧性十足，药明生物、药明康德、药明合联逆市飘红，金斯瑞生物科技续涨逾1%。港股通创新药龙头股批量飘绿，百济神州跌2%止步6连阳，翰森制药跌逾3%；再鼎医药延续涨势，股价创年内新高。100%创新药研发标的——港股通创新药ETF华宝冲高回落，现跌1%再失半年线。8月以来，创新药及产业链利好密集，“吃药”行情持续上演。同期医药生物行业的市场关注度大幅攀升。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-08-12/doc-inimzqcp6895872.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["SMHX","159316","BK1161","TECY","09939","BK4535","PSI","BK1574","SMH","SSG","FLHK","LNGR","06978","EIS","SOXS","IBBQ","159582","USD","BK4588","BK1515","CHPY","MEDX","SOXY","SOXQ","CHPS","VGT","159992","SMHU","SOXX","FWD","MQQQ","SOXL","XSD","TEKX","WX","FTXL","NBDS","CWC","159938","CXO","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658096997","title":"港股異動 | CRO概念股繼續走高 藥明康德司法取得進展 有利於CXO公司在海外爭取新的訂單","url":"https://stock-news.laohu8.com/highlight/detail?id=2658096997","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658096997?lang=zh_tw&edition=fundamental","pubTime":"2026-08-11 11:47","pubTimestamp":1786420064,"startTime":"0","endTime":"0","summary":"消息面上，CRO行业近期迎来多重利好。药明康德司法进展：暂缓美国国防部针对公司的1260H认定执行。药明康德、百济神州等医药行业龙头公布中期业绩大幅增长。药明康德司法进展事件，有利于CXO公司在海外争取新的订单。中国创新药出海持续超预期，充分验证了中国创新药资产的全球竞争力。我们坚定看好创新药产业链的行业前景，建议关注创新药管线有全球竞争力并有大额BD落地或预期的公司、业绩快速增长的CXO公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1478382.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1719994722.HKD","KCAI","LU1997245177.USD","LU2242644610.SGD","IE00B5MMRT66.SGD","LU1251922891.USD","01548","HK0000320264.USD","LU0052750758.USD","LU0700851271.USD","BK4588","LU0348767384.USD","BK1576","LU1997245094.SGD","LU1997244956.HKD","603259","LU0708995583.HKD","06127","HK0000306701.USD","BK4585","WX","BK0216","LU1979443071.USD","LU2488822045.USD","IE00B543WZ88.USD","IE00BPRC5H50.USD","LU0456842615.SGD","02359","LU0320764599.SGD","LU2495084118.USD","BK1141","HK0000320223.HKD","LU1303224171.USD","LU0611395673.USD","LU1934453819.USD","LU1046422090.SGD","CXO","03759","LU1969619763.USD","LU2328871848.SGD","BK1583","LU0348766576.USD","LU2125910500.SGD","LU1808992512.USD","LU2045819591.USD","LU1770034418.SGD","VXUS","HK0000306685.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658936871","title":"衝高回落，CXO狂歡要散場了？","url":"https://stock-news.laohu8.com/highlight/detail?id=2658936871","media":"私募排排网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658936871?lang=zh_tw&edition=fundamental","pubTime":"2026-08-10 19:09","pubTimestamp":1786360140,"startTime":"0","endTime":"0","summary":"整个盘面看下来，CXO这条线热度还在，但短期资金明显开始犹豫了。放到整个CXO行业来说，基本面确实也在回暖。因此，全球创新药融资与大药企研发投入是CXO订单和业绩的核心指标。不过值得注意的是，从6月上旬到现在，CXO板块反弹超35%，创新药概念板块也涨了15%多，短期获利盘应该不少，短期可能有颠簸。CXO这出戏，应该还没到散场的时候。笔者结合公募二季度持仓数据，梳理了基金重仓的CXO公司情况，供读者参考。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-08-10/doc-inimvsvi8100500.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["WX","CXO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658982630","title":"創新藥+CXO齊發力，中報驗證產業向上大趨勢？","url":"https://stock-news.laohu8.com/highlight/detail?id=2658982630","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658982630?lang=zh_tw&edition=fundamental","pubTime":"2026-08-10 17:41","pubTimestamp":1786354860,"startTime":"0","endTime":"0","summary":"截至8月7日，已有22家创新药上市公司发布今年上半年业绩相关报告且普遍向好，其中同比增长的有12家，扭亏的有3家，还有1家减亏。截至8月7日，A股CRO板块中已有8家企业披露半年报或业绩预告，其中6家业绩有望实现两位数及以上增长。结合机构研报，本轮创新药及CXO板块业绩显著提速，主要得益于以下四方面因素的共振。2026年上半年，多家创新药企依托大单品实现销售收入持续放量，验证了企业自建商业化体系的能力。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/jjh/2026-08-10/doc-inimvnpp4945765.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["CXO","BK1574","WX","MEDX","BK1161","LNGR","159992","06978","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658825039","title":"AI製藥點燃「賣鏟人」行情，CXO巨頭刷新多項紀錄！創新藥接棒在即？基金經理最新解讀來了！","url":"https://stock-news.laohu8.com/highlight/detail?id=2658825039","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658825039?lang=zh_tw&edition=fundamental","pubTime":"2026-08-10 17:41","pubTimestamp":1786354860,"startTime":"0","endTime":"0","summary":"8月以来，港股创新药产业链再起攻势，CXO强势领衔！与此同时，公募医药仓位降至5年冰点，低配状态下易引发扩散性行情。】 AI制药关注度升温，CXO或率先受益。港股金斯瑞生物科技的基因合成、定制化蛋白业务受益AI制药需求提升，中报有望上调全年指引。CXO之后，创新药有望接力行情。预计今年随着商业化端和BD端的推动，行业将普遍盈利超预期兑现，叠加Q3、Q4可能的BD，以及与AI相关的合作，后续创新药有望接棒CXO开启新一轮行情。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-08-10/doc-inimvnpi1271075.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159992","BK1574","CXO","VTHR","01477","LNGR","MEDX","BK1191","IBBQ","WX","06978","ARTY","CHAT","AGIX","QTOC","AIPO","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658064603","title":"智通港股早知道 | SK海力士批准54萬億韓元芯片擴產計劃 非京籍家庭購房社保個税繳納年限下調為一年","url":"https://stock-news.laohu8.com/highlight/detail?id=2658064603","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658064603?lang=zh_tw&edition=fundamental","pubTime":"2026-08-10 07:20","pubTimestamp":1786317636,"startTime":"0","endTime":"0","summary":"公司对法院批准公司所申请的初步禁令的裁决表示欢迎。SK海力士批准54万亿韩元芯片扩产计划！调整后，非京籍家庭在全市范围内购买商品住房的社保或个税缴纳年限统一为“1年”，购买商品住房的套数保持不变。《通知》自8日起实施。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1477731.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","BK4141","HYNX","SKHZ","SKHU","BK1592","BK1544","01177","SKHY","WX","03330","07709","IE00BZ08YT58.USD","02611","02889","SK","SKUU","BK1144","HK0000165453.HKD","SKHX","01788","02480","03677","SKHYV","06693","600988","BK1147","BK1116","SKDD","BK1564","BK1191","601211","BK1161","BK1198","IE00BZ08YR35.GBP","IE00BZ08YS42.EUR","BK1521","BK1589","SBHMY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658672913","title":"好「藥」知時節！8月創新藥能否扛大旗？CXO全線爆發，華寶基金港股通醫療ETF放量勁漲5.51%","url":"https://stock-news.laohu8.com/highlight/detail?id=2658672913","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658672913?lang=zh_tw&edition=fundamental","pubTime":"2026-08-09 19:28","pubTimestamp":1786274880,"startTime":"0","endTime":"0","summary":"尾盘阶段，权重股中际旭创突发跳水，收跌逾3.5%，单日振幅超10%。AH近20股涨超10%，药明康德H股新高，华宝基金港股通医疗ETF放量涨5.51%！医药“炸场”，创新药链全线爆发，港股通医疗ETF华宝、港股通创新药ETF华宝、医疗ETF华宝、药ETF华宝等相关ETF批量大涨！CXO龙头集体猛攻，批量涨超10%！港股通医疗ETF华宝放量劲涨5.51%，标的指数近5成仓位布局CXO龙头，其中药明系权重超35%。随着中报季及创新药管线催化预期到来，持续看好医药后市。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-08-09/doc-inimtpwf1700745.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159828","BK1161","LNGR","BK1574","WX","IBBQ","CXO","MEDX","159992","FLHK","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657648344","title":"業績的力量，CXO巨頭單周暴漲20%！創新藥高景氣持續驗證","url":"https://stock-news.laohu8.com/highlight/detail?id=2657648344","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657648344?lang=zh_tw&edition=fundamental","pubTime":"2026-08-07 19:25","pubTimestamp":1786101900,"startTime":"0","endTime":"0","summary":"8月5日，药明康德A股单日成交197.4亿元创历史天量；8月7日，其H股跳涨7%创历史新高，A股涨8.49%创5年新高。当周，药明康德AH股涨幅分别高达20.55%、19.66%。龙头大哥药明康德携多家CXO企业已经用业绩和订单证明行业景气度，创新药企能否同样用超预期业绩来完成产业共振的双向验证。全球创新药投融资回暖。中国创新药BD持续爆发。相关ETF港股通医疗 ETF 华宝：重仓创新药产业链，48%CXO+20%创新药，其中药明系占比超35%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-08-07/doc-inimnzsc3113279.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LNGR","IBBQ","BK1161","BK1574","159992","CXO","06978","WX","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657202693","title":"CXO帶飛醫療，華寶基金醫療ETF（512170）勁漲3%再創階段新高！多股升逾10%，凱萊英漲停封板","url":"https://stock-news.laohu8.com/highlight/detail?id=2657202693","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657202693?lang=zh_tw&edition=fundamental","pubTime":"2026-08-07 11:21","pubTimestamp":1786072860,"startTime":"0","endTime":"0","summary":"8月7日，CXO再爆发！博腾股份、皓元医药、康龙化成集体涨超10%，凯莱英涨停封板，权重龙头药明康德涨超5%再创3年新高！全市场规模最大医疗ETF华宝反包大涨3%，场内价格再创本轮反弹新高！数据显示，医疗ETF华宝标的指数覆盖8只CXO龙头股，权重合计近30%。高效参与CXO交易，关注两大“利器”：医疗ETF华宝：全市场规模最大医药医疗类ETF，聚焦医疗器械+医疗服务，兼顾AI医疗概念。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-08-07/doc-inimnenr0085901.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159891","BK0239","BK1191","CXO","159828","512170","002821","LU1328615791.USD","BK0132","WX","06821"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657698357","title":"港股CXO近日股價集體走高，盈警之後的泰德醫藥(03880)將逆市下跌還是超跌反彈？","url":"https://stock-news.laohu8.com/highlight/detail?id=2657698357","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657698357?lang=zh_tw&edition=fundamental","pubTime":"2026-08-07 10:22","pubTimestamp":1786069332,"startTime":"0","endTime":"0","summary":"7月31日盘后，泰德医药发布了其26H1财年盈警公告。目前泰德医药尚未迎来连续数个交易日的低点逐步抬高以彻底终结下跌趋势，关键的量能均线也尚未出现明显转折。近日，港股医药概念股集体走高，CXO、创新药板块多点爆发，带动恒生医疗保健指数强势反弹。以8月4日行情为例，港股CXO板块出现一波个股集体走高，其中药明康德股价大涨11.17%，康龙化成和泰格医药均涨超5%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1477144.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","BK4588","WX","CXO","NIFE","KCAI","03880","BK4585","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657657002","title":"【券商聚焦】中信建投：CXO 行業復甦明確，海內外醫藥投融資同步回暖","url":"https://stock-news.laohu8.com/highlight/detail?id=2657657002","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657657002?lang=zh_tw&edition=fundamental","pubTime":"2026-08-06 09:04","pubTimestamp":1785978243,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投表示，国内CXO行业经历22-24年的调整阶段后，受益海外投融资率先回暖，24年国内头部CXO公司海外订单展现复苏态势，随着25年国内创新药资产实现大规模对外授权，带动国内投融资25H2持续复苏，行业内需同样企稳回升。26年至今国内创新药行业的长期结构性机会持续兑现，国内投融资持续改善，新药物形式赛道持续火热并进一步放量，该机构认为26年国","market":"other","thumbnail":"https://static.szfiu.com/news/20250106/ODRhMzI4MWM5YTc2MTY1NjgxNGQwMTEwODUwOTcyNzQ0Mg==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/ODRhMzI4MWM5YTc2MTY1NjgxNGQwMTEwODUwOTcyNzQ0Mg==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1987586","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1515","159938","CXO","WX","KCE","BK0276","BK1574","09939","601066"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":51,"code":"91000000","status":"200"}]}}